Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.~Exclusion Criteria:~* Any prior use of rituximab or other B cell depleting agents.~* Any significant health problem other than rheumatoid arthritis~* Clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Consists of Arms 1a and 1b
- Arm 2 (Type: EXPERIMENTAL): Consists of Arms 2a and 2b
- Arm 3 (Type: PLACEBO_COMPARATOR): Consists of Arms 3a and 3b.

Based on this trial design, predict the completion outcome and termination type (if applicable).